Answers are grounded in this paper and cite their sources.
Cancer-associated inflammation is a central driver of tumor progression, immune escape, and therapeutic resistance. However, the inflammatory tumor microenvironment (TME) should not be viewed merely as a collection of soluble cytokines or chemokines. Emerging single-cell, spatial, and functional studies indicate that inflammation operates through dynamic multicellular communication networks involving tumor cells, macrophages, fibroblasts, neutrophils, dendritic cells, NK cells, and T cells. These interactions generate either immunosuppressive circuits or immune-activating niches depending on cellular state, spatial organization, metabolic pressure, and treatment context. In this review, we decode the inflammatory TME as a functional ecosystem organized by tumor-cell-intrinsic inflammatory programs, myeloid and stromal suppressive circuits, regulatory and B-cell states, vascular control of immune trafficking, cDC1–CD8 + T-cell immune niches, and CD8 + T-cell functional reprogramming. We further discuss how cross-cutting regulatory compartments (Tregs, B cells, MDSCs, and endothelial cells) and shared inflammatory, metabolic, and stromal factors-including PGE2, IL-6, lipid metabolic stress, obesity-associated inflammation, acidosis, mitochondrial dysfunction, and ECM/collagen remodeling—connect these modules and shape immune suppression, productive antitumor immunity, and therapeutic response. Finally, we highlight therapeutic strategies aimed at selectively reprogramming harmful inflammatory circuits while preserving productive antitumor immune niches. This framework may support the development of inflammatory TME signatures for predicting immunotherapy response and guiding rational combination therapies.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: